Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

3229 with DOI

7 strong · 20 moderate · 5 weak

Compilations

12026-05-14T09:13:07.077Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

22last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:33:53.151Z

notice · info card · emergency

Searches

220 with no results

queries and counts on the build

Claims checked

7443 supported

43 supported · 31 not

Correspondence

0received

consent field ships in Phase 4

Edges

239

derivations recorded for this entity

Complete over 32 sources, 1 compilation, and 22 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/psilocybe-cubensis/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-10-19issueIssued notice
  4. 2026-09-07srcSingle-Dose Psilocybin Treatment for Major Depressive Disorder
  5. 2026-09-07srcSimultaneous Production of Psilocybin and a Cocktail of β-Carboline Monoamine Oxidase Inhibitors in "Magic" Mushrooms
  6. 2026-09-07srcSafety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
  7. 2026-09-07srcCardiovascular safety of psychedelic medicine: current status and future directions
  8. 2026-09-07srcChallenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse
  9. 2026-09-07srcThe impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression
  10. 2026-09-07srcEfficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review
  11. 2026-09-07srcPsychiatry & the psychedelic drugs. Past, present & future
  12. 2026-09-07srcPsilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms
  13. 2026-09-07srcLow, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
  14. 2026-09-07srcEmerging mechanisms of psilocybin-induced neuroplasticity
  15. 2026-09-07srcPsilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
  16. 2026-09-07srcHigh-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder
  17. 2026-09-07srcEffect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain
  18. 2026-09-07srcPsilocybin desynchronizes the human brain
  19. 2026-09-07srcSingle-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
  20. 2026-09-07srcPhylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster
  21. 2026-09-07srcDynamic myocardial injury and variable hallucination latency in Psilocybe keralensis poisoning: a molecularly confirmed case series from China
  22. 2026-09-07srcREBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
  23. 2026-09-07srcHuman hallucinogen research: guidelines for safety
  24. 2026-09-07srcIntroduction: Evidence for entheogen use in prehistory and world religions
  25. 2026-09-07srcIndigenous psilocybin mushroom practices: An annotated bibliography
  26. 2026-09-07srcAn Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus
  27. 2026-09-07srcPredicting Responses to Psychedelics: A Prospective Study
  28. 2026-09-07srcExtensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids
  29. 2026-09-07srcExploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps
  30. 2026-09-07srcThe Therapeutic Potential of Psilocybin
  31. 2026-09-07srcPharmacokinetics of Psilocybin: A Systematic Review
  32. 2026-09-07srcHallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent
  33. 2026-09-07srcPsilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
  34. 2026-09-07srcPsilocin identified in a DUID investigation
  35. 2026-09-07srcDetermination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man
  36. 2026-09-04issueIssued emergency
  37. 2026-09-04issueIssued info_card
  38. 2026-09-04issueIssued notice
  39. 2026-06-04proposal17 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  40. 2026-06-04publicationPublication — backfill
  41. 2026-05-14revisionRevision 2
  42. 2026-05-14genGeneration — pipeline-v5 · with 9 morepipeline-v5
  43. 2026-05-14rungeneration run
  44. 2026-03-17importImported from Curiosity v1
  45. 2026-03-17publicationPublication — backfill
  46. 2026-03-17revisionRevision 1

The same entries, as forms: six forms.